[Extractive and photometric determination of belladonna alkaloids and atropine sulfate in dosage forms].
Explore the source record for details and available documents.
SEARCH · PubMed Health
Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
High-performance liquid chromatographic separations are described for the analysis of hyoscyamine-atropine and scopolamine in combination pharmaceutical dosage forms containing phenobarbital. A mobile phase containing 0.034 M tetramethylammonium phosphate in water-methanol (21:10, pH 2.0) separated hyoscyamine or atropine from scopolamine on an octadecylsilane column in less than 9 min. Monitoring of the column effluent at 220 nm gave a detection limit of 0.02 microgram for each alkaloid. Hyoscyamine sulfate and/or atropine sulfate were determined as total equivalent hyoscyamine sulfate, and scopolamine hydrobromide was determined as a separate entity. Data from the application of the method to commercial pharmaceutical products are also presented.
Explore the source record for details and available documents.